Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
IOLCP
Mr. Varinder Gupta · Ludhiana, India
₹147.35
▲+0.14%IOLCP’s shares are trading near the lower end of its 52‑week range amid modest earnings, but the company’s robust revenue growth and expanding specialty‑generic portfolio suggest upside potential.
Exchange
NSI
Currency
INR
Day range
₹146.31 – ₹150.48
52-week range
₹67.19 – ₹179.60
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock sits below its 12‑month low, implying a potential upside of 25‑35% if the growth narrative plays out.
18.0% below the 1-year high · trend down
Hedge-fund memo
Today
+0.14%
This week
+1.2%
This month
+4.5%
Bull thesis
Bear thesis
Hidden risks
Narrative read
Neutral
Composite sentiment
Institutional
1.27%
Retail
—
News flow
Recent earnings beat expectations; no major negative news
Read
Investor sentiment is cautious due to debt concerns
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Earnings history unavailable for this symbol.
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| IOLCP | 43.25B | 31.42 | 7.90% | 11.65% | 17.40% |
| AARTIDRUGS | 37.53B | 19.26 | 13.36% | 10.90% | 6.40% |
| CAPLIPOINT | 192.79B | 30.14 | 19.94% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Regulatory setbacks
Mitigation: Diversify product portfolio and maintain strong compliance culture
Pricing pressure from generics
Mitigation: Focus on specialty drugs with higher margins
Currency fluctuations
Mitigation: Hedging and local manufacturing
Business intelligence
Competitive moat
IOLCP’s moat lies in its diversified specialty drug portfolio, established manufacturing capabilities, and a strong domestic distribution network that provide moderate pricing power and barriers to new entrants.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Revenues & EPS figures
Product launch
Thesis builder
Bull case
Sustained revenue growth from specialty drugs and potential margin expansion via cost optimisation
Base case
Maintain current position
Bear case
Debt‑to‑equity pressure and pricing risks could erode earnings
Time horizon
Long‑term (3‑5 years)
Est. CAGR
17–20%
Entry (qual.)
Buy on a 1‑2% pullback
Exit (qual.)
Sell if margin compression >5% or debt ratio >10%
Overall conviction 75%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how IOLCP fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain IOLCP for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
Hold with a view to buying on pullbacks
Annual income statement, oldest → newest. Live via Yahoo.
| 30.90% |
| 19.00% |
| LAURUSLABS | 962.46B | 87.71 | — | 25.39% | 29.10% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹146.31
Resistance (day/52w high)
₹150.48
Volume
9,69,984
Trend
down
RSI (14)
33
MACD
bearish
MA cross
golden
50-day MA
₹140.77
200-day MA
₹97.63
vs 200-DMA
50.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.